Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
An Observational Study of Glycemic Control and Cardiovascular Outcomes Among Patients With Type 2 Diabetes Newly Initiating Glucagon-like Peptide-1 Receptor Agonists (GLP1) Versus Basal Insulin in Routine Care Settings
Sponsor: Brigham and Women's Hospital
A observational or N/A phase clinical study on Diabetes Mellitus, Type 2, this trial is ongoing. The trial is conducted by Brigham and Women's Hospital and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Sep 2022 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Sep 2022 [monthly]
Active Not Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting
▶ Show 1 earlier version
-
Aug 2019 — Aug 2020 [monthly]
Active Not Recruiting
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .